STUDY INDIAN-MADE GENERIC DRUGS LINKED TO 54% HIGHER RISK OF SEVERE SIDE EFFECTS

A recent study conducted by Ohio State University has revealed that generic medications produced in India are associated with a 54% increased risk of severe adverse effects, which may include hospitalization, disability, and even mortality, when compared to their counterparts manufactured in the United States.


The researchers established connections between specific drugs and their manufacturing facilities, highlighting notable discrepancies in quality.

Experts attribute these findings to inadequate regulatory oversight, as inspections by the FDA in foreign facilities are often scheduled in advance, potentially enabling manufacturers to conceal quality deficiencies.

The study advocates for enhanced transparency in drug sourcing and more rigorous global regulatory measures.

Source: SciTechDaily

US Drug Shortage Reaches Record Levels

The United States is currently experiencing its most significant drug shortage in ten years, with 125 medications reported to be in short supply by the end of 2023, as indicated by a report from the United States Pharmacopeia (USP).

These shortages predominantly affect injectable generic drugs, which have a substantial impact on patient care.

The underlying causes are multifaceted, including the low profitability of generic medications, the concentration of manufacturing sites, and stringent quality control measures.

The USP emphasizes the need for comprehensive solutions to stabilize the supply chain and guarantee access to vital medications.

Source: Epoch Times.

[attachment deleted by admin]